Journal of Clinical Oncology
Articles in this Issue
Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer.
e20557 Background: While new therapies known as immune checkpoint inhibitors (ICIs) have improved overall survival (OS) in metastatic non–small cell lung...
Forecasting incidence and mortality rates of bladder cancer in older adults using autoregressive integrated moving average (ARIMA).
e16615 Background: Bladder cancer remains a significant global health burden, particularly in older adults, with its incidence and mortality varying widel...
Desensitization protocols for platinum-based chemotherapy in metastatic cervical cancer: Real-world survival outcomes comparable to global trials.
e23089 Background: Metastatic cervical cancer remains a treatment challenge, as effective therapies are limited and the prognosis is poor. While platinum-...
The mediating role of inflammation in the association between platinum-based chemotherapy and cardiovascular adverse events in older non-small cell lung cancer patients.
e20026 Background: Chemotherapy increases the risk of cardiovascular toxicity, leading to cardiovascular adverse events (CVAE) in cancer patients. However...
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.
e13006 Background: The optimal treatment for HER2-positive advanced breast cancer (ABC) in later lines remains unclear, particularly after progression on...
Does radiation therapy contribute to breast cancer–related lymphedema after axillary node dissection? A simplified lymphatic microsurgical preventative healing approach (S-LYMPHA).
e12588 Background: Patients with breast cancer (BC) undergo axillary lymph node dissection (ALND) under certain indications. One of the main side effects...
Development and validation of an adapted tool to measure health-related social needs for the prostate cancer population in Nigeria.
e23103 Background: The lack of a culturally appropriate and locally validated tool is a key obstacle to the identification of unmet social needs in the ca...
Artificial intelligence-powered real-time model for predicting survival in advanced <i>EGFR</i> -mutant NSCLC.
8636 Background: Novel targeted therapies have led to improved survival in EGFR -mutant NSCLC. However, survival outcomes and canc...
Claudin-18.2 expression in gastro-oesophageal adenocarcinoma in a Western population: Overlap with other biomarkers and prognostic value.
4021 Background: Claudin 18.2 (CLDN18.2) is a novel biomarker for response to anti-CLDN18.2 therapy in gastroesophageal adenocarcinoma (GEA). Based on pre...
Progressive locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with donafenib: A real world study.
e18126 Background: Donafenib was approved for the treatment of RAI-R DTC patients by National Medical Products Administration (NMPA) in 2022, The main obj...
Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial.
9522 Background: In melanoma, there is a need for biomarkers for predicting treatment efficacy. Thymidine kinase 1 (TK) is a cytosolic enzyme that plays a...
HRD status and genomic characteristics of Chinese NSCLC patients.
e20507 Background: Homologous recombination deficiency (HRD) is a condition marked by dysfunction in homologous recombination repair (HRR), leading to gen...
Recurrence-free survival as a surrogate endpoint for overall survival in resectable esophageal cancer: An individual patient data analysis of phase III RCTs.
4068 Background: Overall survival (OS) is regarded as the gold standard efficacy endpoint but requires long follow-up. This study aimed to determine the v...
AI-based classification of laryngeal dysplasia and lymphocytic activity quantification from routine histology.
6080 Background: Laryngeal Dysplasia (LD) is a premalignant condition arising in the lining of the larynx. It is graded based on cytological and architect...
Leveraging high variant allele frequencies (VAF) of DNA damage repair (DDR) mutations (muts) in liquid biopsy (LBx) as a surrogate for germline testing: Implications for precision medicine.
10576 Background: LBx based next-generation sequencing (NGS) provides a minimally invasive means to detect true DDR muts as well as DDR muts that represen...
Camrelizumab plus nab-paclitaxel and cisplatin as first-line treatment for metastatic triple-negative breast cancer: A prospective, single-arm, open-label phase II trial.
1101 Background: Platinum-based chemotherapy plays an important role in the treatment of TNBC. Our previous research has demonstrated the superiority of n...
Who benefits from gilteritinib combination therapy amongst FLT3 <sup>mut</sup> R/R AML? Genomic insights.
e18522 Background: The outcome of FLT3 mut R/R AML is dismal. Use of Giltertinib monotherapy results in modest benefits with an im...
Neoadjuvant niraparib in men with DNA repair gene deficient clinically localized prostate cancer: Clinical and molecular results from a phase 2 investigator-initiated trial.
5104 Background: Many men with clinically localized prostate cancer experience disease progression and recurrence despite curative local therapy. Neoadjuv...
Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA), ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (TRINITY).
TPS9593 Background: NIVO (anti-PD1) alone or in combination with IPI (anti-CTLA-4) or RELA (anti-LAG3) are approved immune checkpoint blockade (ICB) agent...
Mutational profiling of appendiceal tumors from diagnostic specimens and circulating tumor DNA.
e14552 Background: Appendiceal cancer (AC) is a rare malignancy with a high tendency for peritoneal metastasis, and reliable radiographic and serologic ma...
A phase II study of durvalumab, doxorubicin, and ifosfamide in recurrent and/or metastatic pulmonary sarcomatoid carcinoma (KCSG LU-19-24).
8566 Background: Pulmonary sarcomatoid carcinomas (PSCs) are very rare and aggressive tumors with poor prognosis. While conventional cytotoxic agents have...
Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: A National Cancer Database study.
e21590 Background: Wide Local Excision (WLE) is the standing surgical choice for Acral Lentiginous Melanoma (ALM), yet research is scarce in evaluating ot...
Impact of HER2-ultralow heterogeneity and optimal threshold on trastuzumab deruxtecan (T-DXd) efficacy in metastatic breast cancer: A national multicenter cohort study (HEROIC).
1117 Background: Trastuzumab deruxtecan (T-DXd) has been approved for patients (pts) with HER2-ultralow metastatic breast cancer (MBC). HER2 discordance c...
Prospective cohort study of palbociclib in HR+/HER2- metastatic breast cancer in Japan.
1056 Background: The combination of palbociclib (PAL) with an aromatase inhibitor or fulvestrant has been shown to improve progression-free survival (PFS)...
Prevalence of current cigarette smoking and relationships with demographic and psychosocial factors among patients with breast cancer in a nationwide study.
e22550 Background: The purpose of this study was to assess the prevalence of current cigarette smoking among pre-treatment breast cancer patients and to e...